Pregled bibliografske jedinice broj: 820647
Donor-specific antibodies require preactivated immune system to harm renal transplant
Donor-specific antibodies require preactivated immune system to harm renal transplant // EBioMedicine, 9 (2016), 366-371 doi:10.1016/j.ebiom.2016.06.006 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 820647 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Donor-specific antibodies require preactivated immune system to harm renal transplant
Autori
Süsal, Caner ; Döhler, Bernd ; Ruhenstroth, Andrea ; Morath, Christian ; Slavcev, Antonij ; Fehr, Thomas ; Wagner, Eric ; Krüger, Bernd ; Rees, Margaret ; Balen, Sanja ; Živčić-Ćosić, Stela ; Norman, Douglas J. ; Kuypers, Dirk ; Emonds, Marie-Paule ; Pisarski, Przemyslaw ; Bösmüller, Claudia ; Weimer, Rolf ; Mytilineos, Joannis ; Scherer, Sabine ; Tran, Thuong H. ; Gombos, Petra ; Schemmer, Peter ; Zeier, Martin ; Opelz, Gerhard
Izvornik
EBioMedicine (2352-3964) 9
(2016);
366-371
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Single antigen bead ; HLA antibodies ; donor-specific antibodies ; sCD30 ; kidney transplantation ; graft outcome
Sažetak
Background It is an unresolved issue why some kidney transplant recipients with pretransplant donor-specific HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious effect. Methods The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft survival was analyzed in 385 presensitized kidney transplant recipients. Findings A deleterious influence of pretransplant DSA on graft survival was evident only in patients who were positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was virtually identical in patients with or without DSA (83·1±3·9% and 84·3±2·8%, P=0·81). A strikingly lower 3-year graft survival rate of 62·1±6·4% was observed in patients who were both sCD30 and DSA positive (HR 2·92, P<0·001). Even in the presence of strong DSA with ≥5, 000 MFI, the 3-year graft survival rate was high if the recipients were sCD30 negative. Interpretation Pretransplant DSA have a significantly deleterious impact on graft survival only in the presence of high pretransplant levels of the activation marker sCD30.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus
- MEDLINE